Roxadustat Combined With Sacubitril Valsartan Sodium Tablets in the Treatment of Cardiorenal Anemia Syndrome
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
A randomized and parallel controlled trial design of comparing the new treatment group of
Roxadustat combined with Sacubitril Valsartan Sodium Tablets with the traditional treatment
group of recombinant human erythropoietin (EPO) combined with ACEI or ARB in Chinese patients
with cardiorenal anemia syndrome.
Phase:
N/A
Details
Lead Sponsor:
The Affiliated Hospital of Qingdao University
Treatments:
Sacubitril and valsartan sodium hydrate drug combination Valsartan